Patents by Inventor Thomas Joseph SCHUETZ

Thomas Joseph SCHUETZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR ENHANCING THE KILLING OF TARGET CELLS BY NK CELLS
    Publication number: 20200109195
    Abstract: The present disclosure provides immunotherapeutic compositions and methods for enhancing an immune response and for treating cancer or inflammatory conditions mediated by autoreactive B cells in a subject. In some aspects, multispecific antigen-binding constructs are provided that recognize at least one tumor antigen or B-lineage cell antigen and NKp30 and/or another activating NK receptor. In some aspects, multispecific antigen-binding constructs are provided that recognize at least two tumor antigens or two antigens expressed by B-lineage cells, NKp30, and another activating NK receptor. The multispecific antigen-binding constructs and methods disclosed herein can be used for the treatment of cancer, even a cancer characterized by a CD16 deficient microenvironment and/or characterized by target cells (e.g., cancer cells) having a low level of expression of the tumor antigen.
    Type: Application
    Filed: May 21, 2019
    Publication date: April 9, 2020
    Applicant: COMPASS THERAPEUTICS LLC
    Inventors: Jennifer Watkins, Michael March Schmidt, Monia Draghi, Amanda Frank Oliphant, Sara Marie Halmos, Thomas Joseph Schuetz, Jason Michael Lajoie, Allison Nelson
  • COMPOSITIONS AND METHODS FOR ENHANCING THE KILLING OF TARGET CELLS BY NK CELLS
    Publication number: 20200079867
    Abstract: The present disclosure provides immunotherapeutic compositions and methods for enhancing an immune response and for treating cancer or inflammatory conditions mediated by autoreactive B cells in a subject. In some aspects, multispecific antigen-binding constructs are provided that recognize at least one tumor antigen or B-lineage cell antigen and NKp30 and/or another activating NK receptor. In some aspects, multispecific antigen-binding constructs are provided that recognize at least two tumor antigens or two antigens expressed by B-lineage cells, NKp30, and another activating NK receptor. The multispecific antigen-binding constructs and methods disclosed herein can be used for the treatment of cancer, even a cancer characterized by a CD16 deficient microenvironment and/or characterized by target cells (e.g., cancer cells) having a low level of expression of the tumor antigen.
    Type: Application
    Filed: September 26, 2019
    Publication date: March 12, 2020
    Applicant: COMPASS THERAPEUTICS LLC
    Inventors: Jennifer Watkins, Michael March Schmidt, Monia Draghi, Amanda Frank Oliphant, Sara Marie Halmos, Thomas Joseph Schuetz, Jason Michael Lajoie, Allison Nelson
  • MULTISPECIFIC IMMUNOMODULATORY ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20190031785
    Abstract: Provided herein are multispecific immunomodulatory antigen-binding constructs (MIACs) and compositions comprising the constructs. Also provided are methods of using the constructs and methods of making the constructs.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 31, 2019
    Inventors: Thomas Joseph SCHUETZ, Piotr BOBROWICZ, Helen SABZEVARI, Michael March SCHMIDT, Robert V. TIGHE, III, Simon METENOU
  • MULTISPECIFIC IMMUNOMODULATORY ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20180318417
    Abstract: Provided herein are multispecific immunomodulatory antigen-binding constructs (MIACs) and compositions comprising the constructs. Also provided are methods of using the constructs and methods of making the constructs.
    Type: Application
    Filed: January 13, 2016
    Publication date: November 8, 2018
    Inventors: Thomas Joseph SCHUETZ, Piotr BOBROWICZ, Helen SABZEVARI, Michael March SCHMIDT, Robert V. TIGHE, III, Simon METENOU